Insider Transaction Report for Andrew N. Schiff

This filing details insider transactions by Andrew N. Schiff, a director at Aclaris Therapeutics, Inc. (ACRS). On June 4, 2026, Schiff acquired 42,350 stock options with an exercise price of $4.71 and 10,987 Restricted Stock Units (RSUs), vesting in installments through July 2026 and June 2027, respectively. On June 5, 2026, 11,580 RSUs vested, and Schiff disposed of 11,580 shares of Common Stock. Following these transactions, Schiff indirectly holds 434,455 shares of Common Stock through Aisling Capital IV LP. The transactions were made under the company's equity incentive plan and director compensation policy. Schiff disclaims beneficial ownership beyond his pecuniary interest.